Understanding how immune system activation contributes to pulmonary arterial hypertension (PAH)
Immunoglobulin-Driven Activation of the Complement Cascade is a Critical Determinant of PAH Initiation and Progression
This study is looking at how certain parts of the immune system might contribute to the worsening of pulmonary arterial hypertension (PAH), with the goal of finding new treatments that could help reduce harmful inflammation in the lungs for people living with this condition.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10911060 on NIH RePORTER |
What this research studies
This research investigates the role of the immune system, specifically the complement cascade and immunoglobulins, in the development and progression of pulmonary arterial hypertension (PAH). By examining how these immune components trigger inflammation and tissue injury in the lungs, the study aims to uncover the mechanisms that sustain this disease. The research includes both laboratory experiments and potential clinical applications, focusing on targeted therapies that could inhibit harmful immune responses in PAH patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension, particularly those experiencing inflammatory or autoimmune symptoms.
Not a fit: Patients with PAH caused by non-inflammatory factors or those who do not have an autoimmune component may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively manage or even reverse the progression of pulmonary arterial hypertension.
How similar studies have performed: Previous research has shown that targeting the complement system can be effective in treating other inflammatory diseases, suggesting potential success for this approach in PAH.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Stenmark, Kurt R. — University of Colorado Denver
- Study coordinator: Stenmark, Kurt R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.